Document is current
Any future updates will be listed below
-
Authors
Riva, Antonella
Amadori, Elisabetta
Vari, Maria Stella
Spalice, Alberto
Belcastro, Vincenzo
Viri, Maurizio
Capodiferro, Donatella
Romeo, Antonino
Verrotti, Alberto
,
Aiello, Maria Francesca
Bagnasco, Irene
Battistella, Pier Antonio
Bergamoni, Stefania
Boldrini, Benedetta
Bratta, Pasquale
Brusaferro, Andrea
Brusco, Mario
Burchiani, Beatrice
Burdino, Elisa
Cardinali, Beatrice
Cassani, Morena
Cavalli, Elena
Cavallini, Anna
Duccio, Maria Cordelli
D’agata, Gaetano
Di Corcia, Giovanna
D’onofrio, Gianluca
Fagiolari, Giulia
Fattorusso, Antonella
Felicioni, Matteo
Gaiotti, Federica
Galati, Cristina
Gasola, Luisa
Giaquinto, Giuseppina
Gizzi, Chiara
Grasso, Domenico Leonardo
Isidori, Chiara
Marcucci, Maria Teresa
Mazzoni, Valentina
Mencaroni, Elisabetta
Monacelli, Gianluca
Nicita, Francesco
Orsini, Alessandro
Pellegrino, Annamaria
Peruzzi, Cinzia
Piccolo, Gianluca
Pistola, Ilaria
Prezioso, Giovanni
Pulitano, Patrizia
Raieli, Vincenzo
Saladino, Marina
Sapuppo, Annamaria
Sica, Rossella
Spagnoli, Carlotta
Tagliente, Maria
Tascini, Giorgia
Terrone, Gaetano
Tulli, Eleonora
Vinti, Valerio
Striano, Pasquale https://orcid.org/0000-0002-6065-1476
-
Funding
Funding for this research was provided by:
Proveca Pharma Ltd
- License Information
-
More Information
Article History
Received: 22 November 2021
Accepted: 24 June 2022
First Online: 19 July 2022
Declarations
:
: Participants agreed to participate in the survey and accepted informed consent. All methods were performed in accordance with the ethical standards as laid down in the Declaration of Helsinki and its later amendments or comparable ethical standards. With regards to the Italian setting, Ethics Committees (EC) have the function of evaluating, approving and monitoring clinical, observational, epidemiological, diagnostic, public health studies, with medical devices, with the use of human biological material, and with implications for environmental ethics (MINISTERIAL CIRCULAR No. 6, SEPTEMBER 2nd 2002).Following what is reported in the MINISTERIAL CIRCULAR No. 6, SEPTEMBER 2nd 2002, exploratory surveys do not fall within the types of investigations subject to authorization by the EC as they do not operate directly on patients or therapies.
: Not applicable.
: AR has received honoraria from Kolfarma s.r.l, Proveca Pharma Ltd., and PTC Therapeutics. PS received honoraria from GW pharma, Kolfarma s.r.l., Proveca Pharma Ltd., and Eisai Inc. The other authors do not report conflict of interest.
